SIRT1基因多态性与肺癌化疗敏感性的关系  

Effects of SIRT1 Genes Polymorphisms on the Chemosensitivity of Patients with Lung Cancer

作　　者：符一岚[1,2,3] 王瑛[2] 尹继业[2] 任华益[3] 周宏灏[2] 刘昭前[2] 

机构地区：[1]中南大学药学院,湖南长沙410013 [2]中南大学临床药理研究所遗传药理学湖南省重点实验室,湖南长沙410078 [3]中南大学湘雅医学院附属肿瘤医院,湖南长沙410013

出　　处：《肿瘤药学》2013年第6期426-431,共6页Anti-Tumor Pharmacy

基　　金：国家高技术发展计划重大专项(863项目)(NO:2012AA02A517);国家自然科学基金项目(NO:81173129;81373490)

摘　　要：目的探讨SIRT1基因多态性与肺癌对以铂类为基础的化疗敏感性的关系。方法选取338名肺癌患者(其中184名对化疗耐药和154名对化疗敏感)为研究对象,所有患者均接受以铂类(顺铂、卡铂)为基础的化疗。分析其SIRT1的所有单核苷酸多态性,最后筛选出4个tag SNPs进行基因分型。OR和CI用来评估SIRT1基因多态性与肺癌患者化疗效果的相关性。结果在>60岁的肺癌患者中,rs3758391的基因多态性与铂类化疗疗效显著相关(OR=0.38, P=0.049)。rs3740051、rs12778366的遗传多态性与铂类化疗疗效之间无显著相关性。结论 SIRT1 rs3758391基因多态性可以显著影响肺癌患者铂类化疗的敏感性,SIRT1可能作为肺癌铂类化疗疗效评估的标志物。Objective To explore the relationship between the SIRT1 genetic polymorphisms and chemosensitivity to plati- num-based chemotherapy in lung cancer patients. Methods A total of 338 lung cancer patients （184 resistant and 154 sensitive） were selected and treated by platinum-based chemotherapy in this study. All single nucleotide polymorphisms in SIRT1 gene were analyzed and four tagging SNPs were finally screened for genotyped. The odds ratios （OIL） with 95 % confidence intervals （CI） were used to assess the effect of S1RT1 Genes Polymorphisms on the chemosensitivity of patients with lung cancer. Results We found a significant association of SIRT1 rs3758391 polymorphism with platinum-based chemotherapy effectiveness in lung cancer patients who were older than 60 years （OR=0.38, P = 0.049）. While no significant correlation was discovered between rs3740051, rs12778366 genetic polymorphism and platinum-based chemotherapy effect . Conclusion Our findings suggest that the SIRT1 rs3758391 genetic polymorphism can affect platinum-based chemotherapy sensitivity in lung cancer patients, and SIRT1 may be act as a potential biomarker on lung cancer chemotherapy response.

关 键 词：S1RTl 单核苷酸多态性 肺癌 化疗敏感性 

分 类 号：R734.2[医药卫生—肿瘤]